Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Air Products & Chemicals, Inc. (APD) vs BIO-TECHNE Corp (TECH) Price & Performance

Air Products & Chemicals, Inc.Trade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Air Products & Chemicals, Inc. vs BIO-TECHNE Corp — how do they compare? Air Products & Chemicals, Inc. trades at $303.43 (market cap $66.70B), while BIO-TECHNE Corp trades at $71.33 (market cap $11.11B). The key difference: Air Products & Chemicals, Inc. is far larger — about 6× BIO-TECHNE Corp's market cap, and Air Products & Chemicals, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.

APDTECH
Market Cap
$66.70B$11.11B
Sector
Basic MaterialsHealth
52-Week High
$314.19$71.38
52-Week Low
$230.42$43.31
Enterprise Value
$84.11B$11.19B
Dividend Yield
2.42%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Air Products & Chemicals, Inc.

APD trades at $299.53, up 1.24% today, with a bullish technical signal from moving averages and strong analyst support. Recent earnings beats and strategic project exits, like the Louisiana Clean Energy Complex, have boosted investor confidence. The company maintains solid profitability margins but faces pressure from a negative net income in 2025 due to a pre-tax charge. Cash flow trends show volatility, with significant investing outflows for growth initiatives.

The outlook is positive with a consensus price target of $324.89, implying ~8% upside. Risks include high debt levels, execution on new projects, and macroeconomic sensitivity. Long-term growth is supported by renewable energy investments, but near-term profitability recovery is key for sustained gains.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.30, up 0.21% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, while fundamentals reveal high valuation multiples (P/E 101.84) amid declining net margins (6.01% in 2025). Recent earnings were mixed with one beat and two misses in the last four quarters. Cash flow improved in 2026 projections, and the balance sheet remains solid with $152.86M cash.

The pending acquisition at $73.00 per share limits near-term upside but provides a floor. Risks include shareholder litigation questioning the deal's fairness and execution volatility. Analyst consensus is evenly split between Buy and Hold, with the price target slightly below current levels. The primary opportunity is the acquisition premium, while fundamental weakness in profitability poses a risk if the deal falters.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Air Products & Chemicals, Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.

Read more on APD

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH